Figure 1 Sorrento Therapeutics, Inc. Figure 2 Sorrento Therapeutics, Inc. Figure 3 Sorrento Therapeutics, Inc….
VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) — Lucy Scientific Discovery Inc. (“Lucy” or…
VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) — Lucy Scientific Discovery Inc. (“Lucy” or…
Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel LEXINGTON, Mass.,…
Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel LEXINGTON, Mass.,…
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody…
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody…
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission…
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission…
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM),…
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM),…
Qualigen Therapeutics, Inc. Co-operation between RAS-F series and AMG-510 and MRTX1133 Preclinical Data Show Potential…
Qualigen Therapeutics, Inc. Co-operation between RAS-F series and AMG-510 and MRTX1133 Preclinical Data Show Potential…
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5…
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5…
– Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory…
– Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory…
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high…
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high…
Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels,…